Akash Goel1,2, Saam Azargive3, Wiplove Lamba4, Joel Bordman4, Marina Englesakis5, Sanjho Srikandarajah6, Karim Ladha1,7, Tania Di Renna1, Harsha Shanthanna8, Scott Duggan3, Philip Peng1, John Hanlon1, Hance Clarke9,10. 1. Department of Anesthesiology, University of Toronto, Toronto, ON, Canada. 2. T.H. Chan School of Public Health, Harvard University, Cambridge, MA, USA. 3. Department of Anesthesiology and Perioperative Medicine, Queens University School of Medicine, Kingston, ON, Canada. 4. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 5. Library and Information Services, Toronto General Hospital, Toronto, ON, Canada. 6. Department of Anesthesiology, North York General Hospital, North York, ON, Canada. 7. Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, Toronto, ON, M5G 2C4, Canada. 8. Department of Anesthesiology, McMaster University, Hamilton, ON, Canada. 9. Department of Anesthesiology, University of Toronto, Toronto, ON, Canada. hance.clarke@uhn.ca. 10. Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, Toronto, ON, M5G 2C4, Canada. hance.clarke@uhn.ca.
Abstract
BACKGROUND: An increasing number of patients with opioid use disorder (OUD) are treated with opioid agonist-antagonists such as buprenorphine/naloxone. Perioperative management of patients on buprenorphine/naloxone is inconsistent and remains a controversial topic with mismanagement posing a significant risk to the long-term health of these patients. METHODS: We performed a systematic literature search involving Medline, Medline In-Process, Embase, Cochrane Central, Cochrane Database of Systematic Reviews, PsycINFO, Web of Science (Clarivate), Scopus (Elsevier), CINAHL (EbscoHosst), and PubMed (NLM). RESULTS: Eighteen studies were included in the final sample, including one controlled study and four observational studies . Neither the controlled study nor the observational studies assessed addiction treatment retention, harm reduction, or long-term mortality rates as primary or secondary outcomes. Of the observational studies, authors showed equivalent peri- and postoperative pain control among buprenorphine continued patients. All but one authors described adequate analgesia among the case reports in which buprenorphine ≤ 16 mg sublingually (SL) daily was continued during the perioperative period. Long-term harm reduction was not reported with only three case reports including any long-term abstinence or relapse rates. CONCLUSIONS: The current understanding of the risks and benefits of continuing or stopping buprenorphine perioperatively is limited by a lack of high-quality evidence. Observational studies and case reports indicate no evidence against continuing buprenorphine perioperatively, especially when the dose is < 16 mg SL daily. In patients with significant potential for relapse, such as those with a recent history of OUD, the discontinuation of buprenorphine should have a strong rationale supported by patient and surgical preferences. Future studies require standardized reporting of median doses, details on the route of delivery, dosing schedules and any dosing changes, and rates of addiction relapse, including long-term morbidity and mortality where possible.
BACKGROUND: An increasing number of patients with opioid use disorder (OUD) are treated with opioid agonist-antagonists such as buprenorphine/naloxone. Perioperative management of patients on buprenorphine/naloxone is inconsistent and remains a controversial topic with mismanagement posing a significant risk to the long-term health of these patients. METHODS: We performed a systematic literature search involving Medline, Medline In-Process, Embase, Cochrane Central, Cochrane Database of Systematic Reviews, PsycINFO, Web of Science (Clarivate), Scopus (Elsevier), CINAHL (EbscoHosst), and PubMed (NLM). RESULTS: Eighteen studies were included in the final sample, including one controlled study and four observational studies . Neither the controlled study nor the observational studies assessed addiction treatment retention, harm reduction, or long-term mortality rates as primary or secondary outcomes. Of the observational studies, authors showed equivalent peri- and postoperative pain control among buprenorphine continued patients. All but one authors described adequate analgesia among the case reports in which buprenorphine ≤ 16 mg sublingually (SL) daily was continued during the perioperative period. Long-term harm reduction was not reported with only three case reports including any long-term abstinence or relapse rates. CONCLUSIONS: The current understanding of the risks and benefits of continuing or stopping buprenorphine perioperatively is limited by a lack of high-quality evidence. Observational studies and case reports indicate no evidence against continuing buprenorphine perioperatively, especially when the dose is < 16 mg SL daily. In patients with significant potential for relapse, such as those with a recent history of OUD, the discontinuation of buprenorphine should have a strong rationale supported by patient and surgical preferences. Future studies require standardized reporting of median doses, details on the route of delivery, dosing schedules and any dosing changes, and rates of addiction relapse, including long-term morbidity and mortality where possible.
Authors: Thomas Christoph; Babette Kögel; Klaus Schiene; Murielle Méen; Jean De Vry; Elmar Friderichs Journal: Eur J Pharmacol Date: 2004-12-30 Impact factor: 4.432
Authors: Sudipta Sen; Sailesh Arulkumar; Elyse M Cornett; Julie A Gayle; Ronda R Flower; Charles J Fox; Alan D Kaye Journal: Curr Pain Headache Rep Date: 2016-03
Authors: Joseph Pergolizzi; Anna Maria Aloisi; Albert Dahan; Joerg Filitz; Richard Langford; Rudolf Likar; Sebastiano Mercadante; Bart Morlion; Robert B Raffa; Rainer Sabatowski; Paola Sacerdote; Luis M Torres; Avi A Weinbroum Journal: Pain Pract Date: 2010 Sep-Oct Impact factor: 3.183
Authors: T Anthony Anderson; Aurora N A Quaye; E Nalan Ward; Timothy E Wilens; Paul E Hilliard; Chad M Brummett Journal: Anesthesiology Date: 2017-06 Impact factor: 7.892
Authors: Jessica J Wyse; Anders Herreid-O'Neill; Jacob Dougherty; Sarah Shull; Katherine Mackey; Kelsey C Priest; Honora Englander; Jessica Thoma; Travis I Lovejoy Journal: J Gen Intern Med Date: 2021-09-20 Impact factor: 6.473
Authors: Saam Azargive; Joel S Weissman; Akash Goel; Harsha Shanthanna; Karim S Ladha; Wiplove Lamba; Scott Duggan; John G Hanlon; Tania Di Renna; Philip Peng; Hance Clarke Journal: BMJ Open Date: 2019-05-22 Impact factor: 2.692